Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Alcohol Dependence Clinical Trials

A listing of Alcohol Dependence medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (31) clinical trials

Varenicline for Alcohol Dependence

The varenicline for alcohol dependence trial investigates the efficacy of varenicline versus placebo for maintaining abstinence in the postacute treatment of alcohol dependent subjects. The main study hypothesis is that subjects treated with varenicline have more abstinent days during the study.

Phase

Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO)

OH dependence is associated with DA receptor changes. Both, the apomorphine test and the D2Rec SPECt are usefull for monitoring DA receptor status. We aimed at studying whether DA receptor hypofunction, assessed by means of the apomorphine test and the D2Rec SPECT, is a marker of relapse in detoxified OH ...

Phase

Project RAP: Reaching Adolescents for Prevention

Many studies have shown that a brief motivational interview in the context of a routine or emergency health care visit may assist adults to reduce high-risk drinking and drug-taking. Center researchers are conducting a 1,400-person, randomized clinical trial involving teen patients at the Boston Medical Center Pediatric Emergency Department in ...

Phase

Psychotherapy Enhancement for Therapeutic Community (TC) Retention - 1

Therapeutic Community (TC) treatment can be effective psychosocial modality for addiction, but premature dropout remains a major problem. Personality disorders are very common in residential programs, and TCs regard personality disturbance as core to all people with addiction. Severe personality dysfunction is associated with higher dropout rates from TCs, and ...

Phase

Buproprion for Binge Drinking

The design is a 1:1 random assignment to placebo or bupropion XL (extended release) (300mg/d). The study biostatistician, will prepare the randomization schedule and include blocking by gender and nicotine dependence. Randomization will be based on a stratified block design, with gender and nicotine dependence as the stratification variables with ...

Phase

Gabapentin for Bipolar & Cannabis Use Disorders

Bipolar disorder (BD) is the Axis I condition most strongly associated with cannabis use disorder (CUD); there is a six-fold increase in the prevalence of CUD in individuals with BD relative to the general population. Individuals with co-occurring CUD and BD (CUD+BD) have substantially worse clinical outcomes than those with ...

Phase

Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?

Number of patients and target population: 114 patients with a diagnosis of alcohol dependence and 25 healthy participants (described later). The patients included in the trial will be treated for 26 weeks with once-weekly subcutaneous injection of Bydureon (exenatide) 2 mg or placebo. The medication will be provided as a ...

Phase

Mifepristone Treatment of Alcohol Use Disorder

This is an 8-week, randomized, double-blind, placebo-controlled, 3 arm, parallel groups, dose-ranging study of 1-week of treatment with mifepristone (0, 600, 1200 mg/d) given in conjunction with 8 weeks of manual-guided counseling, and a follow-up visit at Week 12.

Phase

Peer MI for Substance-using Emerging Adults

This project randomized peer dyads, consisting of one EA (Emerging Adult; 18-29 years old) with a substance use problem (i.e. target client) and one peer, to one of two conditions. In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI) ...

Phase

A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence

Two to four sites will participate in this study. Aims of the study are 1) to characterize the acute effects of PO psilocybin 25 mg/70 kg, 30 mg/70 kg, and 40 mg/70 kg in alcohol dependent patients; 2) to evaluate the effect of psilocybin treatment on drinking outcomes for 32 ...

Phase